Ajinomoto becomes first partner for Albireo's lead drug elobixibat
This article was originally published in Scrip
Executive Summary
Albireo has struck the first alliance for its lead development project, the bowel disorder drug elobixibat (A3309), with Ajinomoto Pharmaceuticals for a number of Asian markets including Japan.
You may also be interested in...
Albireo Making Headway In Rare Pediatric Liver Diseases With IBAT Inhibition
Biotech hopes to launch a Phase III trial in the rare disorder PFIC before year’s end. It thinks its therapy could offer similar benefits to surgery in reducing pruritus and improving liver parameters.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.